SEARCH RESULTS FOR:

VICE PRESIDENT OF CANADA, KAL TIRE’S MINING TIRE GROUP

"With predictive maintenance tools being able to take all aspects, even seasons, into account, the system also helps clients with forecasting inventory."

Petrochemicals & Chemicals

Singapore

Johnson Lai

VICE PRESIDENT, CHEMICAL SPECIALTIES LIMITED (CSL)

"As a toll manufacturer, we find ourselves in a sweet spot because we can offer a speed-to-market solution in our current facility to producers, many of which wish the localization to be done yesterday."

Petrochemicals & Chemicals

Singapore

Ganapathy Swamy

MD SINGAPORE AND HEAD OF ONSITE ACCOUNTS, LINDE ASEAN

"Linde is present in both green and blue hydrogen pathways, and we are committed to support Jurong Island players taking concrete steps."

Mining

Canada

James Withall

CEO, RUPERT RESOURCES

"We started to demonstrate the prospectivity of our land package and in particular the new 4 million oz Ikkari discovery, which has been the main driver for the valuation of the company over the last 18 months."

Mining

Canada

Chris Frostad

PRESIDENT AND CEO, PUREPOINT URANIUM GROUP

"Now that more funding is available to the uranium sector we can expand our work across our ten 100% owned projects where early discoveries have already been made."

Mining

Chile

Philippe Hemmerdinger

PRESIDENT, ASSOCIATION OF INDUSTRIAL MINING SUPPLIERS (APRIMIN)

Chile’s Association of Industrial Mining Suppliers (APRIMIN)

Mexico

Petrochemicals & Chemicals

Patricio Gutiérrez

CHAIRMAN OF THE BOARD & CEO, GRUPO IDESA

Grupo Idesa provides an overview of its different petrochemical units in Mexico.

United States

Pharma & Life Sciences

Donna LaVoie

PRESIDENT & CEO, LAVOIEHEALTHSCIENCE

"The surge of communication need has increased exponentially as companies recognize the necessity of conveying a differentiated story amid the unprecedented number of financings and IPOs over the last two years."

United States

Pharma & Life Sciences

Lori Hu

MANAGING DIRECTOR, VERTEX VENTURES HC

"The M&A market has been relatively slow over the past year as pharma executives wait on the sidelines for the valuation correction to play out, but I believe that we will see M&A activities increase in this coming year."